Top Industry Leaders in the Respiratory Drugs Market
Latest Respiratory Drugs Companies Update
AstraZeneca (UK) Launched the first triple-fixed combination therapy for COPD in Europe, Breztri Aerosolizer®, offering improved symptom control and reduced exacerbations. Received FDA approval for Fasenra® (benralizumab) for severe eosinophilic asthma, expanding their portfolio of biologics for difficult-to-treat respiratory diseases.
GlaxoSmithKline (GSK) (UK) Partnered with Verve Therapeutics to develop new gene therapy candidates for severe asthma and other respiratory diseases. Announced positive Phase 3 results for Nucala® (mepolizumab) in chronic rhinosinusitis with nasal polyps, potentially opening up new market opportunities.
Novartis (Switzerland) Received European Commission approval for Xolair® (omalizumab) for the treatment of chronic severe asthma in children aged 6 to 11 years, broadening their pediatric reach. Focused on developing inhaled therapies for lung cancer, partnering with companies like BeiGene to bring targeted treatments to patients
Teva Pharmaceutical Industries Ltd. (Israel) Introduced a generic version of Advair®, a popular inhaled therapy for COPD and asthma, offering cost-effective options for patients and impacting market dynamics. Invested in digital health solutions like connected inhalers and mobile apps to improve medication adherence and disease management for respiratory patients.
List of Respiratory Drugs Key companies in the market
- VAPOTHERM
- AptarGroup, Inc.
- Drägerwerk AG & CO.
- Allied Healthcare
- Cardinal Health
- NSPIRE HEALTH INC.
- Koninklijke Philips N.V.
